Contraindications: What studies truly support (and what they don’t)

Contraindications sometimes feel like a rigid “do-not.” In practice, however, they are only as solid as the studies they rely on. That is exactly why you should separate efficacy from safety and consistently ask how well the underlying evidence fits your individual situation.

In this article, I’ll show you how to read the evidence on contraindications properly: from the evidence hierarchy to lifestyle levers, with concrete examples in migraine, immunotherapy, anticoagulants, and menopause.

Why contraindications don’t apply to everyone (and why evidence matters)

Short answer: Contraindications are population-dependent: what a studied patient group considered “safe enough” or “too risky” in one trial can look different in other constellations. The key is whether the recommendation evaluates safety outcomes and relevant subgroups separately.

In real-world use, contraindications often fail because many recommendations are phrased as if they were universally applicable. In reality, warning statements often come from studies with specific inclusion/exclusion criteria—and therefore exclude certain patient types. If you fall into one of those “missing” categories (e.g., severe comorbidities, other concomitant medications, specific organ impairment, different age groups), your actual risk may diverge from the study foundation.

Another lever is study type: Systematic Reviews and meta-analyses can pool safety data across many studies and therefore support more stable conclusions. Single studies or case reports may provide hints, but they rarely yield a robust contraindication logic because they seldom capture enough “negative cases” that would be decisive for a true contraindication.

When reading, check whether a source separates efficacy from adverse effects, and whether it addresses the question of “for whom does it apply?” via subgroup analyses or relevant safety endpoints. If studies do not sufficiently cover contraindication-adjacent topics (e.g., kidney function, concurrent medication, relevant pre-existing conditions) or evaluate only the “overall population,” you can treat contraindications derived from them only as a conservative starting point—not as a hard list.

This is especially true when, in the reviews, the active ingredient is studied mainly in a “treatment group” without analyses that specifically consider the exact situations you suspect would be the contraindication. In those cases, the correct conclusion is not “do not use,” but: data are limited.

Evidence hierarchy: RCTs and meta-analyses over observational data to animal studies

Short answer: The higher the evidence level, the more reliably safety questions (including risks adjacent to contraindications) can be synthesized. RCTs and meta-analyses often provide the best basis; observational data are more prone to bias; animal data are generally not directly translatable to human contraindications.

The evidence hierarchy is not only an academic concept—it determines how “hard” a contraindication can reasonably be. In medicine, safety is often a topic where the relevant subgroup is small or adverse events are rare. That is exactly why meta-analyses help: they increase statistical “substance” by integrating many studies.

• Systematic Reviews / meta-analyses: particularly helpful when they evaluate safety endpoints consistently. An example is parenteral therapies for acute migraine in an evidence-based assessment for the emergency context (Robblee et al., 2026, PMID 41321235). Such assessments are not automatically contraindications, but they offer a better basis for contextualizing risks and boundaries.
• Observational studies: may reveal patterns but are vulnerable to biases. Frequently, “healthier” or “less risky” patients are more likely to receive certain therapies. This can create apparent safety advantages that do not appear in RCTs—and vice versa.
• Animal data: for contraindications, they usually only serve as a biological clue. They capture metabolism, dose-response trajectories, and adverse effect profiles in humans poorly. Deriving hard contraindications from this would be methodologically weak.

It’s also important to note: even on an RCT basis, evidence for contraindications can be indirectly limited if trials exclude certain patient groups. In practice, you then need a different form of evidence robustness: Reviews that aggregate exactly those safety aspects and include as many relevant studies as possible in the analysis.

If a study explicitly evaluates “safety” together with “efficacy,” that’s a good signal for what can be inferred. In some topics—for example, menopause-associated vasomotor symptoms with a specific medication option—efficacy and safety are assessed together in a meta-analysis (Elnaga et al., 2024, PMID 38640780). This is valuable because it treats safety endpoints as more than “an afterthought.”

When lifestyle options exist: nutrition, not an immediate supplement regimen

Short answer: Before considering pharmacologic second-line options or “supplement regimens,” check whether there are lifestyle interventions supported by RCTs/Reviews for your specific goal. Lifestyle isn’t automatically “risk-free,” but it is often less burdened by contraindication issues—and should therefore be prioritized.

Many people jump to supplements when asked about contraindications because they feel subjectively “harmless.” Methodologically, that is not clean: supplements can also have interactions or amplify certain risks. If you use lifestyle as a lever, the approach is at least in many areas more controllable and closer to evidence logic that RCTs can capture.

A direct example showing how nutrition-related interventions can address feasibility alongside efficacy/safety: in obesity patients prior to non-bariatric operations, a pilot study investigated a low-energy nutrition strategy and additionally combined it with a systematic assessment (McKechnie et al., 2026, PMID 41821307). This is not a “contraindication list” in the narrow sense, but it provides a pattern: nutrition can be a therapy-adjacent intervention and therefore must be considered in safety evaluation (e.g., tolerability, impact on course, and possible risks in certain settings).

The contraindication point: lifestyle interventions may have fewer medication-class-specific risks, but they can still cause problems in certain situations (e.g., malnutrition, specific metabolic disorders, or timing relative to surgery/healing). The evidence base differs by indication.

Before adding additional means, think in a clear sequence:

1. Are there already RCT/Review-like lifestyle options for exactly your objective?
2. What endpoints were reported (not only “weight loss,” but also adverse events/discontinuation rates/tolerability)?
3. Does your personal profile match the populations studied?

If lifestyle options exist, they are often the cleanest way to minimize risk—while increasing effectiveness rather than merely “supplementing.” So the path “lifestyle first, then supplements” is not a lifestyle religion; it is an evidence strategy.

Concrete safety questions from studies: migraine, immunotherapy, and interaction risks

Short answer: For migraine and other conditions, Reviews usually show rather risk-benefit boundaries instead of rigid “do-not” lists. In immunotherapy, there are safety approaches like checklists. For anticoagulants, contraindication-adjacent issues are often tied to patient factors (e.g., kidney function) and context.

Migraine: acute treatment and safety in an emergency context

For acute migraine treatment in emergencies, an evidence-based assessment of parenteral pharmacologic therapies provides a structured view of safety considerations (Robblee et al., 2026, PMID 41321235). Such work is especially relevant because emergency settings involve different patient selection and different monitoring possibilities than outpatient care.

In addition, systematic reviews exist on non-invasive neuromodulation for acute migraine that combine efficacy and safety from RCTs (Clark et al., 2022, PMID 34698941). This typically results in a balanced risk-benefit perspective: more “useful/unfavorable under certain circumstances” rather than a universal contraindication.

Immunotherapy: safety checklists instead of gut feeling

With immunomodulating therapies, the problem is often not a single event but the combination of relevant risks to consider before starting treatment. A systematic review explicitly proposes the concept of a safety checklist to capture relevant risks systematically (Haysen et al., 2026, PMID 42080423). This matters because contraindications often arise from the individual risk combination (infection susceptibility, pre-existing conditions, concomitant medication, etc.), not from one single parameter.

Anticoagulants: contraindications are rarely just “yes/no”

For anticoagulants, contraindication questions are particularly complex in practice because they rarely hinge on “the substance is contraindicated.” Instead, they depend on: which patient, which context, which kidney function, which long-term risk, which concomitant medication. Systematic Reviews and network meta-analyses show that safety derivation is often linked to patient characteristics and kidney/long-term context (Cohen et al., 2015, PMID 26716830; Wu et al., 2026, PMID 42128628; Nasir et al., 2026, PMID 41995292).

That does not mean there are no “hard” exclusions—but it means you should not interpret generic warning statements as if they were universally decisive. Instead, use the study evidence to contextualize your risk profile.

Menopause therapies: what safety is supported (and what remains limited)

Short answer: For certain menopause options, meta-analyses exist that aggregate efficacy and safety. But even there, contraindications are often indirect when trials do not report clear subgroups for “contraindication-like” situations—so deriving a hard “forbidden” rule remains limited.

A central point for contraindications is: “safety” is not always the same as “contraindication.” Many studies report adverse events, but not with enough granularity to construct a reliable list of contraindications for every possible risk constellation.

For Fezolinetant for vasomotor symptoms in menopause, a systematic review with meta-analysis reports efficacy and safety (Elnaga et al., 2024, PMID 38640780). For the contraindication question, the advantage is that meta-analyses can pool safety endpoints, reducing the risk that you overinterpret a rare event from a single context.

Even so, a hard methodological boundary remains:

• If the study does not evaluate contraindication-adjacent subgroups (e.g., certain relevant pre-existing diseases or concomitant medications that often trigger contraindications in practice), you cannot cleanly say: “For person X, it’s forbidden.”
• In such situations, the correct conclusion is a “limitation of evidence”: the data do not sufficiently cover certain constellations.

Practically, for you that means:

1. Take warning notes and safety interpretations from the Review as a starting point.
2. Then match them to your personal history: concomitant medications, organ-based risks (e.g., liver/kidney context, cardiovascular profile), and history of relevant adverse effects.
3. If your profile was not represented in the studies, make a conservative decision (“data limited”) rather than relying on a falsely precise “forbidden” logic.

If you do this correctly, it protects you from two common mistakes: overtrusting “general” warning statements, or the opposite—false reassurance because nothing appeared in the overall population.

Evidence base and derivability of contraindications (table)

Short answer: A contraindication can only be derived well when safety endpoints and relevant subgroups are available in a robust form. The following overview shows how different types of evidence (and endpoint breadth) affect transferability.

Studies-to-practice check: how to read contraindications without overextending data

Short answer: You can evaluate contraindications more seriously by checking first the evidence type and endpoints, separating efficacy from safety, and looking for subgroup/subcontext analyses. If subgroups are missing, you must keep the conclusion conservative (“data limited”).

Here is a practical process that prevents you from overstretching study claims:

1) Clarify the evidence class first

Question: Is it a systematic review/meta-analysis, or mostly single findings? Meta-analyses have the advantage of pooling safety data across multiple studies. For example, this is the case for menopause safety with Fezolinetant (Elnaga et al., 2024, PMID 38640780) or for acute migraine (Robblee et al., 2026, PMID 41321235; Clark et al., 2022, PMID 34698941). If you have such a source in front of you, safety aspects are more likely presented in a non-random way.

2) Check whether the contraindication question is actually addressed

Many recommendations fail because the study may report “adverse effects,” but not in the form you need for contraindications: subgroups for relevant comorbidities, relevant concomitant medication, or organ-based risk categories.

For immunotherapy, this exact problem is one reason why safety checklists are proposed as a systematic approach (Haysen et al., 2026, PMID 42080423). That suggests that in practice, a “hard contraindication” is often replaced by screening.

3) Separate efficacy from safety

A medication can be effective in the overall population, but the evidence on contraindication-like exclusions may be thin or indirect. Therefore, it is methodologically wrong to infer “works well” automatically means “low risk for me”—and just as wrong to infer “adverse effects exist” automatically means a blanket contraindication.

4) Phrase conservatively when subgroups are missing

If you cannot find subgroup analyses (or they are not reported in a relevant way), your correct conclusion is: data limited—not “contraindicated.” This principle helps you especially with topics where safety profiles strongly depend on context, such as anticoagulants (Cohen et al., 2015, PMID 26716830; Nasir et al., 2026, PMID 41995292; Wu et al., 2026, PMID 42128628).

5) Check lifestyle first

If lifestyle interventions exist, they are often the “first safety line.” The nutrition strategy before surgery shows that nutrition-adjacent approaches are not only “optional,” but systematically evaluated in study contexts (McKechnie et al., 2026, PMID 41821307). This means lifestyle can be part of an evidence-based safety strategy, not just a “nice to have.”

What you take away

• Contraindications are not universal truths; they are dependent statements from specific study populations.
• Systematic Reviews and meta-analyses usually support contraindication-adjacent warnings better than individual studies—because safety endpoints are more often aggregated.
• Separate efficacy from safety and look specifically for subgroup/subcontext evidence; if it’s missing, the right phrasing is usually “data limited.”
• Lifestyle levers first: nutrition/exercise/sleep/light are often less burdened by contraindication issues than pharmacologic “second lines”—and they can still be evaluated in studies (e.g., nutrition before surgery: McKechnie et al., 2026, PMID 41821307).
• In complex areas (e.g., migraine, immunotherapy, anticoagulants, menopause), a risk check by context is often more sensible than a blanket “do not” rule.